310
Participants
Start Date
July 31, 2014
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
GEN-003 Vaccine (30μg of each antigen)
HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
GEN-003 Vaccine (60μg of each antigen)
HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
Matrix-M2 Adjuvant (25μg)
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Matrix-M2 Adjuvant (50μg)
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Matrix-M2 Adjuvant (75μg)
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Placebo
0.9% Normal Saline (NaCl)
Magee-Womens Hospital of UPMC, Pittsburgh
UNC Global HIV Prevention and Treatment Clinical Trials Unit, Chapel Hill
Indiana University Infectious Disease Research, Indianapolis
University of Illinois Department of Medicine, Chicago
Center for Clinical Studies - Houston, Houston
Center for Clinical Studies, Houston
Center for Clinical Studies - Clear Lake/Webster, Webster
University of Utah, Salt Lake City
Medical Center for Clinical Research, San Diego
Quest Clinical Research, San Francisco
Westover Heights Clinic, Portland
UW Virology Research Clinic, Seattle
Tekton Research, Austin
University of Alabama Vaccine Research Unit, Birmingham
The Fenway Institute, Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Lead Sponsor
Genocea Biosciences, Inc.
INDUSTRY